Long-term exposure to testosterone therapy and the risk of high grade prostate cancer

Jacques Baillargeon, Yong Fang Kuo, Xiao Fang, Vahakn B. Shahinian

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.

Original languageEnglish (US)
Pages (from-to)1612-1616
Number of pages5
JournalJournal of Urology
Volume194
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Testosterone
Prostatic Neoplasms
Therapeutics
Medicare
Neoplasms
Injections
Health Maintenance Organizations
Androgens
Autopsy
Epidemiology
Logistic Models
Demography
Population

Keywords

  • androgens
  • neoplasm grade
  • prostatic neoplasms
  • SEER program
  • testosterone

ASJC Scopus subject areas

  • Urology

Cite this

Long-term exposure to testosterone therapy and the risk of high grade prostate cancer. / Baillargeon, Jacques; Kuo, Yong Fang; Fang, Xiao; Shahinian, Vahakn B.

In: Journal of Urology, Vol. 194, No. 6, 01.12.2015, p. 1612-1616.

Research output: Contribution to journalArticle

@article{fb7c7a3b0ea3476fadf379b7a7dcbeeb,
title = "Long-term exposure to testosterone therapy and the risk of high grade prostate cancer",
abstract = "Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95{\%} CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95{\%} CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95{\%} CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.",
keywords = "androgens, neoplasm grade, prostatic neoplasms, SEER program, testosterone",
author = "Jacques Baillargeon and Kuo, {Yong Fang} and Xiao Fang and Shahinian, {Vahakn B.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.juro.2015.05.099",
language = "English (US)",
volume = "194",
pages = "1612--1616",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Long-term exposure to testosterone therapy and the risk of high grade prostate cancer

AU - Baillargeon, Jacques

AU - Kuo, Yong Fang

AU - Fang, Xiao

AU - Shahinian, Vahakn B.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.

AB - Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.

KW - androgens

KW - neoplasm grade

KW - prostatic neoplasms

KW - SEER program

KW - testosterone

UR - http://www.scopus.com/inward/record.url?scp=84943296834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943296834&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.05.099

DO - 10.1016/j.juro.2015.05.099

M3 - Article

VL - 194

SP - 1612

EP - 1616

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -